首页   关于我们   服务项目   新闻动态   诚聘英才   资料文案   客户须知   联系我们
科研立项
普通科研立项/部省市级/项目申报书/标书/计划书/评职称科研等
结题报告
结题报告/研究报告/阶段报告/成果报告/调研报告/开题报告等
科学基金
自然/社会科学基金/产学研/青年/教育/软科学/863/学科点等
论文成果
期刊论文/毕业论文/应用文/代写/发表/翻译/成果编撰/出版等
 
沙美特罗替卡松联合噻托溴铵治疗COPD并发重度支气管哮喘的临床效果观察
添加时间: 2019-4-21 12:27:19 文章来源: 文章作者: 点击数:179

彭科营

广东医科大学附属深圳龙华中心医院 呼吸内科 邮编:518110

 []:目的: 研究沙美特罗/替卡松联合噻托溴铵治疗慢性阻塞性肺病(COPD)并发重度支气管哮喘的临床效果,为COPD并发重度支气管哮喘的治疗提供更多选择。方法: 201412~20162院入院治疗的68COPD并发重度支气管哮喘患者进行了研究,随机分为两组,对照组给予沙美特罗/替卡松联合复方异丙托溴铵进行治疗,观察组采用沙美特罗/替卡松联合噻托溴铵进行治疗,两组治疗方案均以1年为一个疗程,治疗结束后比较两组患者的呼吸功能、临床症状发作次数及发作间隔、患者的生活质量以及两组治疗方案的不良反应发生情况。结果: 观察组和对照组患者在治疗后的第一秒用力呼气量(FEV1)占预计值的百分比、FEV1FEV1/用力肺活量(FVC)均明显高于治疗前,在治疗后上述三项指标比较中,观察组患者升高幅度明显高于对照组,差异有统计学意义(P0.05);在临床症状发作次数的比较中,观察组患者明显少于对照组,并且观察组患者的发作间隔时间明显长于对照组,两组比较差异明显,统计数据有意义(P0.05);经过治疗,两组患者的生活质量评分与治疗前比较均有明显的升高,治疗后观察组与对照组患者比较中,观察组的生活质量评分明显高于对照组(P0.05);两组患者的药物不良反应均以心悸和声嘶为主,两组不良反应的总发生率均为8.8%,差异无统计学意义(P0.05)。结论: 沙美特罗/替卡松联合噻托溴铵治疗COPD并发重度支气管哮喘的临床效果显著,治疗后呼吸功能有明显的改善,临床症状的发作次数显著减少,间隔延长,患者的生活质量得到了明显的提升,且没有增加额外的不良反应,值得临床推广应用。

[关键词]:沙美特罗,替卡松,噻托溴铵,哮喘,COPD

Clinical Observation of salmeterol / ticyclofen Combined with Tiotropium on Treatment of COPD Complicated with Severe Bronchial Asthma

Peng ke ying

Department of respiratory medicine; Longhua Central Hospital Affiliated to Shenzhen Medical University; Guangdong 邮编:518110

[Abstract]

Objective: To study the clinical effect of salmeterol / ticyclofen combined with tiotropium on treatment of COPD complicated with severe bronchial asthma, for providing more choices for the disease. Methods: 68 patients from Dec 2014 to Feb 2016 with COPD and severe bronchial asthma were enrolled in this study. They were randomly divided into two groups. The control group received salmeterol / ticyclofen combined with ipratropium bromide, The treatment group was treated with salmeterol / ticyclofen and tiotropium bromide. The treatment period was one year. After the treatment, the respiratory function, the clinical symptoms, the onset interval, the life quality and the incidence of adverse reactions was compared between the two groups.  Results: When compared with before, the FEV1 and FEV1 / FVC was significantly higher in the two groups, The amplitude of the observation group was significantly higher than that of the control group (P <0.05); the amplitude of the observation group was significantly higher than control (P <0.05); For the clinical symptoms, the observation group was significantly less than the control, and the onset interval of the observation group was significantly longer than the control (P <0.05); After treatment, the score of life quality of the two groups were significantly higher than before(P <0.05). The score in the observation group was significantly higher than control (P <0.05)